In a report released on February 28, Tycho Peterson from Jefferies maintained a Buy rating on Bruker (BRKR – Research Report), with a price target of $80.00.
Tycho Peterson has given his Buy rating due to a combination of factors that highlight Bruker’s promising outlook. The recent installation of a 1.2 GHz NMR system at the University of Warwick in the UK, funded by a significant investment from UKRI, underscores Bruker’s expanding presence in the European market. This installation is expected to support a variety of research applications and foster collaboration between universities and the private sector, enhancing Bruker’s market position.
Furthermore, Bruker’s guidance for 2025 suggests a realistic approach to potential market slowdowns, with expectations for multiple GHz-class NMR placements. Despite potential revenue impacts from NIH dynamics, Bruker benefits from positive developments in sectors like semiconductors and microbiology, alongside recent strategic deals. The company’s attractive valuation metrics, coupled with a promising margin runway, contribute to the Buy rating, reflecting confidence in Bruker’s ability to navigate market challenges and capitalize on growth opportunities.
Peterson covers the Healthcare sector, focusing on stocks such as Thermo Fisher, NeoGenomics, and Bruker. According to TipRanks, Peterson has an average return of 5.2% and a 51.47% success rate on recommended stocks.
In another report released on February 26, Bank of America Securities also maintained a Buy rating on the stock with a $76.00 price target.